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Mesenchymecal determinant of the shape and size of the lung, the extent and patterning of
epithelial branching, and the formation of the pulmonary vasculature and interstitial mesenchymal
components of the adult lung. Fibroblast growth factor 9 (FGF9) is a critical regulator of lung mesenchymal
growth; however, upstream mechanisms that modulate the FGF mesenchymal signal and the downstream
targets of mesenchymal FGF signaling are poorly understood. Here we have identiﬁed a robust regulatory
network in which mesenchymal FGF signaling regulates β-Catenin mediated WNT signaling in lung
mesenchyme. By conditionally inactivating β-Catenin in lung mesenchyme, we show that mesenchymal
WNT-β-Catenin signaling is essential for lung development and acts to regulate the cell cycle G1 to S
transition and the FGF responsiveness of mesenchyme. Together, both FGF and WNT signaling pathways
function to sustain mesenchymal growth and coordinate epithelial morphogenesis during the pseudogland-
ular stage of lung development.
© 2008 Elsevier Inc. All rights reserved.IntroductionMouse lung development is initiated on embryonic day 9.5 (E9.5)
with the formation of two endodermal buds off the ventrolateral
foregut. Lung buds invade the surrounding splanchnic mesoderm
and overlying mesothelium to establish a lung primordium initially
composed of three tissue layers, epithelium (endoderm), mesoderm
and mesothelium (Hogan, 1999). As the lung buds grow and enter
the pseudoglandular stage of development (E9.5–16), the mesen-
chyme forms two morphologically and molecularly distinct layers,
the sub-mesothelial layer and the sub-epithelial layer (White et al.,
2006). These mesenchymal layers express unique intercellular
signaling molecules, such as WNT2a and FGF10 in the sub-
mesothelial layer and Noggin in the sub-epithelial layer (Bellusci
et al., 1996; Mailleux et al., 2005; Weaver et al., 2003; White et al.,
2006). Growth and morphogenesis of the lung require intercellular
signaling interactions between all primary cell layers of the lung
(Cardoso and Lu, 2006; Shannon and Hyatt, 2004; Warburton et al.,
2005).
Fgf9 is expressed in the outermost layer of the lung, the meso-
thelium, and in lung epithelium, and has been identiﬁed as a key
factor that signals to mesenchyme to regulate proliferation, differ-
entiation and the expression of other factors that in turn regulate
epithelial development (Colvin et al., 1999; Colvin et al., 2001).
Mesenchymal forms of FGF receptors 1 and 2 have been shown tol rights reserved.mediate the FGF9 signal (White et al., 2006). Epithelial FGFs, such as
FGF9, often regulate the expression of mesenchymal FGFs and other
signaling molecules that in turn regulate epithelial and mesenchymal
development. In a screen of candidate genes that are expressed in lung
mesenchyme and that could be regulated by mesenchymal FGF sig-
naling, Wnt2a was found to be signiﬁcantly down-regulated in lungs
of mice lacking Fgf9 (Fgf9−/−) (see Fig. 1). This suggested a link between
FGF and WNT-β-Catenin signaling in lung mesenchyme and that
regulation ofWNT-β-Catenin signalingmay be responsible for some of
the lung phenotypes observed in Fgf9−/− embryos.
WNT signaling is essential for embryonic patterning and cell fate
determination (Moon, 2005). At least three intracellular signaling
pathways mediate WNT signaling, the WNT-β-Catenin pathway, the
WNT/Ca2+ pathway and the planar cell polarity (PCP) pathway. WNT-
β-Catenin signaling through frizzled (FZ) receptors and low-density
lipoprotein receptor-related protein (LRP) 5 and 6 co-receptors lead
to activation of disheveled (DVL), inhibition of GSK3β, and stabiliza-
tion and cytosolic accumulation of β-Catenin. Increased cytosolic
levels of β-Catenin lead to its nuclear translocation and to the
formation of active transcription factor complexes of β-Catenin with
members of the T Cell Factor (LEF1, TCF1, TCF3, TCF4) transcription
factor family, PITX2 and SOX17 (Brantjes et al., 2002; Briata et al.,
2003; Kioussi et al., 2002; Vadlamudi et al., 2005; Zorn et al., 1999).
Downstream targets of WNT-β-Catenin signaling include the cell
cycle regulator, CyclinD1, and transcription factors, N-myc, Lef1 and
Pitx2 (Hovanes et al., 2001; Kioussi et al., 2002; Shu et al., 2005;
Tetsu and McCormick, 1999). In embryonic lung, nuclear β-Catenin,
LEF1 and PITX2 have been detected in the epithelium and in
Fig. 1. FGF9 regulates WNT signaling in lung mesenchyme. (A–H) Whole-mount in situ hybridization showingWnt2a (A–D) and Lef1 (E–H) expression in E13.5 lung. All tissue pairs
were hybridized and developed together in the same tube. Comparison of control (A) and Fgf9−/− (B) lungs shows an absence ofWnt2a expression in lungmesenchyme in Fgf9−/− tissue.
In contrast, induced overexpression of FGF9 in lung epithelium from E11.5 to E13.5 (Fgf9dox(48)) (D) results in increased Wnt2a expression compared with the control lungs (C).
Comparison of control (E) and Fgf9−/− (F) shows decreased expression of Lef1 in Fgf9−/− lung mesenchyme. Comparison of control (G) and Fgf9dox(48) (H) lungs shows increased
expression in FGF9 overexpressing mesenchyme. Cryo-sections (inset) of Lef1 whole-mount in situ hybridization stained control (E′) and Fgf9−/− lungs (F′) reveal decreased Lef1
expression localized in the sub-mesothelial mesenchyme. Color development in panels C, D, G, Hwere for shorter periods of time compared to panels A, B, E, F. (I–L)Wnt7b expression
levels in lung epitheliumwas not affected in either FGF9 loss of function (Fgf9−/−, J) or gain of function (Fgf9dox(48), L) lungs comparedwith the controls (I, K). Scale bar in panel A, 200 μm.
427Y. Yin et al. / Developmental Biology 319 (2008) 426–436adjacent mesenchyme (Hjalt et al., 2000; Mucenski et al., 2003;
Tebar et al., 2001). Similarly, TOPGAL and BATGAL, WNT-β-Catenin
reporter genes that detect a subset of sites of WNT-β-Catenin
activity, are active in lung epithelium and in adjacent mesenchyme
(De Langhe et al., 2005; Maretto et al., 2003; Okubo and Hogan,
2004; Pongracz and Stockley, 2006; Shu et al., 2005).
WNT-β-Catenin signaling has been investigated in lung epithelium
through conditional inactivation of β-Catenin or overexpression of the
WNT signaling antagonist dickkopf1 (DKK1). Both approaches
resulted in defects in distal lung bud formation, possibly due to
disruption of FGF10-FGFR2b signaling (Mucenski et al., 2003; Shu et
al., 2005). Three Wnts (Wnt2a, Wnt2b, Wnt7b) that typically signal
through the WNT-β-Catenin pathway are expressed during lung
development. Inactivation ofWnt7b, which is expressed in distal lung
epithelium, results in severe lung hypoplasia due to defects in
branching morphogenesis, cell proliferation, epithelial differentiation
and loss of vascular smooth muscle integrity (Shu et al., 2002).Wnt2a
is highly expressed in the distal mesenchyme (Bellusci et al., 1996;
Monkley et al., 1996) but Wnt2a targeted mice were reported to have
normal lung development (Monkley et al., 1996). Wnt2b (formerly
called Wnt13) is also expressed in lung mesenchyme during early
stages of lung development (Katoh et al., 1996; Katoh et al., 2000;
Zakin et al., 1998). This leaves open the possibility of functional
redundancy between these two related and similarly expressed genes.
TwoWnts (Wnt5a,Wnt11) that typically signal through non-canonical
pathways are expressed in lung epithelium and mesenchyme. Wnt5a
is expressed in lung epithelium and adjacent mesenchyme and inac-
tivation ofWnt5a leads to over-branching of the epithelial airway and
thickening of the mesenchymal interstitium (Li et al., 2005, 2002).Wnt11 is expressed both in the lung epithelium and mesenchyme,
but its function during lung development is not clear (Lako et al.,
1998).
Although WNT-β-Catenin signaling is clearly important for lung
epithelial development, its role in lung mesenchyme has not been
directly examined. Herewe identify an essential role for mesenchymal
WNT-β-Catenin signaling by conditionally inactivating β-Catenin
speciﬁcally in lungmesenchyme.We furthermore identify a reciprocal
signaling loop in lung mesenchyme in which mesothelial/epithelial to
mesenchymal FGF signals regulate Wnt2a expression and WNT-β-
Catenin signaling, and mesenchymal WNT-β-Catenin signaling reg-
ulates FGFR1 and FGFR2 expression and, consequently, the level of FGF
signaling. Disruption of any component of this signaling network
results in defects in lung mesenchymal development and consequent
defects in epithelial morphogenesis.
Materials and methods
Mouse strains
All mouse strains, including Fgf9+/−, β-Cateninf/f, Dermo1-Cre, TRE-Fgf9-IRES-eGfp,
SPC-rtTA, Fgfr1f/f, Fgfr2f/f (f indicates a ﬂoxed allele) and Rosa26 reporter (R26R), have
been previously described (Brault et al., 2001; Colvin et al., 2001; Soriano, 1999;
Tichelaar et al., 2000; Trokovic et al., 2003; White et al., 2006; Yu et al., 2003).
Fgfr1/2Dermo1 conditional knockout mice (Dermo1Cre/+, Fgfr1f/f, Fgfr2f/f) and Fgf9dox(48)
mice (SPC-rtTA, TRE-Fgf9-IRES-eGfp) were made as described (Perl et al., 2002; White et
al., 2006). The β-Cateninf/f strain was acquired through the Jackson Laboratory (Bar
Harbor, ME). For conditional inactivation of β-Catenin in lung mesenchyme, mice were
generated with the genotype, Dermo1Cre/+, β-Cateninf/f (referred to as β-CateninDermo1)
by mating Dermo1Cre/+, β-Cateninf/+ mice with β-Cateninf/f. Control mice were of the
genotype Dermo1Cre/+; Dermo1Cre/+, β-Cateninf/+; β-Cateninf/f; or β-Cateninf/+, all of
which were phenotypically identical to wild type mice. All loss of function mice were
Fig. 2. Mesenchymal FGFR signaling regulates mesenchymal WNT-β-Catenin sig-
naling and mesenchymal proliferation. (A–D) WNT-β-Catenin signaling in control and
Fgfr1/2Dermo1 lung mesenchyme. Whole-mount in situ hybridization ofWnt2a (A, B) and
Lef1 (C, D) expression showing down-regulation in Fgfr1/2Dermo1 lung mesenchyme
(B, D) compared with controls (Dermo1cre/+, Fgfr1+/f, Fgfr2+/f) (A, C) at E14.5. (E, F) Cell
proliferation assessed by BrdU labeling showing decreased labeling inmesenchyme and
epithelium of Fgfr1/2Dermo1 lungs (F) compared to control lungs (E) at E14.5. Scale bars:
panels A and C, 200 μm; panel E, 100 μm.
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of function experiments, were maintained on the FVB background.
Analyses of mouse embryos, histology and immunohistochemistry
To induce FGF9 expression in vivo, the doxycycline-inducible epithelial transcrip-
tional activator (SP-C-rtTA) was used to induce a tetracycline responsive transgene
driving FGF9 (Perl et al., 2002; White et al., 2006). Doxycycline chow (Bio-Serv Inc.,
300 mg/kg green pellets) was administered to pregnant female mice for 48 h prior to
embryo isolation (Fgf9dox(48)).
Embryo tissues were collected in ice-cold PBS, ﬁxed in 4% PFA overnight at 4 °C,
washed with PBS, photographed and embedded in parafﬁn prior to sectioning at 5 µm.
For histology, slides were stained with hematoxylin and eosin (H&E). For immuno-
histochemistry, parafﬁn-embedded or cryo-sections were rehydrated and treated with
0.3% hydrogen peroxide in methanol for 15 min to suppress the endogenous peroxidase
activity. Antigen retrieval was achieved by microwaving the sections in 10 mM citrate
buffer for 5 min followed by gradual cooling to room temperature. Sections were
incubated overnight at 4 °C with the following primary antibodies: PCNA (sc-56, Santa
Cruz Biotechnology Inc, 1:100); β-Catenin (610153, BD Transduction Laboratories,
1:200); LEF1 (sc-8591, Santa Cruz Biotechnology Inc, 1:100); BrdU (347580, Becton
Dickinson Immunocytometry Systems, 1:200); phospho-histone H3 (pHH3, H9908,
Sigma, 1:100); FGFR2 (sc-122, Santa Cruz Biotechnology Inc, 1:100); CyclinD1 (#2926,
Cell Signaling Technology, 1:100); phospho-ERK (M8159, Sigma, 1:100), and TTF-1
(M3575, DAKO Cytomation,1:100), visualized using Broad Spectrom (AEC) Kit (95-9743,
Zymed Laboratories Inc.) or Vectastain® Elite ABC (AEC) kit (PK-4005, Vector
Laboratories).
For BrdU analysis, pregnant females were injected with BrdU at 0.1 mg/kg body
weight, 2 h prior to harvest. Embryos were collected in ice-cold PBS, processed and
sectioned as above.
All staining patterns are representative of at least three embryos.
Cell death analysis
Parafﬁn or cryo-sectioned slides, prepared as described above, were assayed
(TUNEL) using the In Situ Cell Death Detection Kit (Roche Applied Science). Slides were
mounted with DAPI containing Vectashield® mounting medium (H-1200, Vector
Laboratories) for ﬂuorescent detection or counterstained with hematoxylin (MHS-16,
Sigma) for AEC detection and then photographed. All staining patterns are repre-
sentative of at least three embryos.
Whole-mount in situ hybridization
In situ probes were from the following sources: Lef1, Wnt2a (A. McMahon), Wnt7b
(F. Long); Fgf10 (B. Hogan); Spry2; Fgfr1 (S. Werner); N-Myc (E. Morrisey). Probes were
synthesized and labeled with a kit from Roche Applied Science. Whole-mount in situ
hybridizationwas performed as described (Colvin et al., 2001). Following color reaction
andmethanol dehydration, tissues were photographed and then cryo-sectioned (6 μm),
mounted on slides and re-photographed. In situ hybridizations of tissue sections were
performed as previously described (Colvin et al., 1999). All staining patterns are
representative of at least three embryos.
Whole-mount LacZ staining
Lungs were dissected in ice-cold PBS and ﬁxed with 0.5% glutaraldehyde in PBT
(PBS, 0.1% Tween-20) overnight at 4 °C. Tissues were washed in PBT twice for 10 min
prior to incubation with LacZ staining solution (2 mM MgCl2, 35 mM potassium
ferrocyanide, 35 mM potassium ferricyanide, 1 mg/ml X-Gal in PBT) at room tem-
perature in the dark. Following adequate color reaction, tissues were again washed
twice in PBT for 10 min each to stop the reaction. Samples were then soaked in 30%
sucrose overnight, photographed and then embedded and frozen in OTC for cryo-
sectioning (6 µM). Sections were dried for ~3 h at room temperature, washed with PBS
and mounted. All staining patterns are representative of at least three embryos.
Lung organ cultures
Lung explant cultures were performed as described (White et al., 2006). E11.5
control, Fgf9−/− and β-CateninDermo1 embryonic lungs were dissected and cultured on
Transwell ﬁlters (Costar, Corning) for 48 h at 37 °C, 5% CO2. Mouse FGF9 protein
(PeproTech Inc.) was used at a concentration of 2.5 ng/ml in DMEM supplemented with
2 µg/ml heparin. LiCl was used at a concentration of 20 mM (Dean et al., 2005). To
quantify mesenchymal thickness, explants were photographed and mesenchymal
thickness was measured using Canvas X software. Data shown is representative of at
least three independent experiments.
RNA isolation, cDNA synthesis, and qRT-PCR analysis
E14.5 embryonic lung mRNA was isolated using the RNeasy kit (Qiagen Inc.)
following manufacturer's instructions. cDNA was synthesized using the SuperScript II
ﬁrst-strand cDNA synthesis kit (Invitrogen). Quantitative RT-PCR was performed on an
ABI 7500 machine using TaqMan® probes for Gapdh and Fgfr2. Ampliﬁcation and
analysis were performed according to the manufacturer's instructions. All reactionswere normalized to Gapdh. Results were graphed as relative expression compared with
control, where control was scaled to 1.
Construction of a Fgfr2 promoter-luciferase reporter
A mouse genomic DNA fragment extending 6.8 kb 5′ and 533 bp 3′ to the Fgfr2
transcription initiation site was excised from BAC DNA (RP23-466 J2) with BamH1 and
subcloned into the pGL3 basic vector (Promega Inc.) to generate pGL3-Fgfr2p. This
fragment contains Fgfr2 exon 1 and part of intron 1. The pCIG-dominant active β-Catenin
vector (0.2 µg) or control vector (pCIG) (Megason and McMahon, 2002) was co-
transfected into HEK293 cells with pGL3-Fgfr2p and pCMV-β-Gal (Promega) using
Fugene 6 (Roche Applied Science). Luciferase assay was performed 48 h after
transfection using the Luciferase Assay System (Promega). All data were normalized
to β-Gal activity. Data represents four independent experiments. Positive controls (not
shown), using the TOPFLASH reporter, demonstrated activation of WNT signaling.
Results
FGF9 regulates WNT signaling in lung mesenchyme
Wnt2a is prominently expressed in lung mesenchyme and has
been shown to signal through the WNT-β-Catenin pathway (Bellusci
et al., 1996; Karasawa et al., 2002). Examination of E13.5 lung tissue
from mice lacking FGF9 (Fgf9−/− mice) demonstrated a complete
absence of Wnt2a expression in lung mesenchyme (Figs. 1A, B). By
contrast, induced overexpression of FGF9 in lung epithelium from
E11.5 to E13.5 (Fgf9dox(48)) (White et al., 2006) resulted in increased
Wnt2a expression (Figs. 1C, D). To determine if WNT-β-Catenin
signaling was regulated by FGF9 in lung mesenchyme, we examined
the expression of Lef1, a transcriptional target of the WNT-β-Catenin
pathway that is expressed in lung mesenchyme (Porﬁri et al., 1997;
Tebar et al., 2001). In Fgf9−/−mice, Lef1 expressionwas reduced in lung
mesenchyme at E13.5, whereas in mice overexpressing Fgf9 in lung
epithelium from E11.5 to 13.5, Lef1 expression was increased in the
sub-epithelial mesenchymal domain (Figs. 1E–H). Immunohisto-
chemical detection of LEF1 revealed a similar pattern and regulation
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Fig. 1). To determine whether FGF9 signaling has any effect on an
epithelial Wnt, we examined the expression of the WNT-β-Catenin
pathway ligand, Wnt7b (Shu et al., 2002). Expression of Wnt7b was
not affected in either FGF9 loss of function or gain of function mouse
models (Figs. 1I–L). These data suggest that Wnt2a may contribute to
WNT-β-Catenin signaling in lungmesenchyme and is a candidate for a
downstream target of FGF9 signaling.
FGF receptors 1 and 2 have been shown to act redundantly to
mediate the FGF9 signal in lung mesenchyme (White et al., 2006). We
thus hypothesized that inhibition of mesenchymal FGF receptors
should also result in decreased mesenchymal WNT-β-Catenin signal-
ing. To test this hypothesis directly, we conditionally inactivated ﬂoxed
alleles of both Fgfr1 and Fgfr2 in the lung mesenchyme with Dermo1-
Cre and then examined the expression ofWnt2a and Lef1. Dermo1-Cre
is active in lungmesenchyme andmesothelium, but not epithelium. By
E10.5, Dermo1-Cre can efﬁciently activate the ROSA26 reporter allele
(R26R) and β-galactosidase activity throughout lungmesenchyme andFig. 3.Mesenchymal β-Catenin is essential for embryonic lung development. (A–C) Anterior v
at E12.5 (A), E14.5 (B) and E18.5 (C). Note the decreased number of epithelial branches (numbe
H&E stained histologic sections of lungs at the same stages shown in panels A–C. At E12.5 (E)
distal mesenchyme compared with controls (D, F). At E18.5 (I), β-CateninDermo1 lung tissue con
control lungs (H) had developed numerous primitive alveoli surrounded by blood vessels. (J)
β-Gal staining indicating Cre activity throughout embryonic mesenchyme and mesothelium
β-CateninDermo1 lungs have greatly reduced staining in lungmesenchyme as early as E12.5 (L) a
(K, M). Epithelial expression appeared unaffected at these stages of development. No counter
Asterisk indicates mesenchyme; arrow indicates epithelium. Scale bars: panel A, 0.25 mm; pmesothelium (see Fig. 3J below). Consistent with our previous report
(White et al., 2006), Dermo1cre/+, Fgfr1f/f, Fgfr2f/f (hereafter referred to
as Fgfr1/2Dermo1) lungs were smaller than control lungs beginning at
E12.5. Whole-mount in situ hybridization of E12.5 Fgfr1/2Dermo1 lungs
showed reduced Wnt2a (Figs. 2A, B) and Lef1 expression in lung
mesenchyme (Figs. 2C, D), similar towhatwas observed in Fgf9−/−mice.
Consistent with decreased FGFR signaling, mesenchymal proliferation
was decreased at E14.5 (Figs. 2E, F). Together, these data suggest that
FGFR signaling in lung mesenchyme modulates the level of mesench-
ymal WNT-β-Catenin signaling in lung mesenchyme.
Mesenchymal β-Catenin is essential for embryonic lung development
To directly investigate the role of mesenchymal WNT-β-Catenin
signaling in embryonic lung development, β-Catenin (β-Catenin f/f)
(Brault et al., 2001) was conditionally targeted in lung mesenchyme
with Dermo1-Cre (Yu et al., 2003). Mice of the genotype Dermo1Cre/+,
β-Cateninf/f, hereafter referred to as β-CateninDermo1, showed impairediews of gross dissections of control (Dermo1-Cre, β-Cateninf/+) and β-CateninDermo1 lungs
rs) but normal number and orientation of lobes at E12.5. tr, trachea; es, esophagus. (D–I)
and E14.5 (G), β-CateninDermo1 lung tissue had fewer epithelial branches and decreased
tained small epithelial tubes surrounded by dense disorganized mesenchyme, whereas
Cryo-section of a Dermo1-Cre, Rosa26R lung at E10.5 showingmesenchymal cell-speciﬁc
, but not epithelium. (K–N) Immunohistochemistry detection of β-Catenin showing that
nd complete absence ofmesenchymal protein by E14.5 (N), comparedwith control lungs
stainwas used in panels K and L. Panels M and Nwere counterstained with hematoxylin.
anels B and C, 1 mm; panels D, F, H, 100 μm; panel J, 200 μm; panels K, M, 50 μm.
Fig. 4. Mesenchymal and epithelial WNT-β-Catenin signaling following conditional
inactivation of β-Catenin in lungmesenchyme. (A–D) Expression of Lef1 in control (A, C)
and β-CateninDermo1 lung mesenchyme (B, D) at E12.5. A,B are whole-mount in situ
hybridizations. Panels C, D are cryo-sections of the tissue in panels A and B. (E, F)
Immunohistochemical detection of LEF1 showing decreased protein in mesenchyme at
E12.5 in β-CateninDermo1 lungs (F) comparedwith control lungs (E). (G, H)Whole-mount
in situ hybridization showing reduced Wnt2a expression in β-CateninDermo1 lung
mesenchyme (H) compared with control (G). (I, J) Whole-mount in situ hybridization
showing that N-Myc expression in lung epithelium was not affected by inactivating
β-Catenin in lung mesenchyme (J) compared with control (I). (K, L) Whole-mount in situ
hybridization showing that Wnt7b expression in lung epithelium was increased in
β-CateninDermo1 lung (L) compared with control (K). Scale bars: panels A, G, I, K, 200 μm;
panels C and E, 50 μm.
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Dermo1Cre/+, β-Cateninf/+ or Dermo1+/+, β-Cateninf/f were phenotypi-
cally normal (Fig. 3A and data not shown). β-CateninDermo1 lungs had a
normal number and orientation of lobes but fewer epithelial branches
and decreasedmesenchyme. In some cases, lobes weremisshapen and
bent. By E14.5, the lungs were less than half of the normal size and
failed to grow during the remainder of embryonic development
(Fig. 3B). By E18.5, β-CateninDermo1 lungs were small and compact,
lacked smooth borders, and the trachea had completely degenerated
(Fig. 3C). β-CateninDermo1 mice died at birth due to respiratory failure.
Histologic sections of E12.5 and E14.5 β-CateninDermo1 lung tissue
revealed decreased epithelial branching and decreased distal
mesenchyme, but otherwise normal appearing mesenchymal and
epithelial compartments (Figs. 3D–G). At E18.5, control lungs had clear
airspace development, accompanied by thinning of the mesenchyme
and close approximation of fetal capillaries to ﬂattened epithelial cells.
By contrast, β-CateninDermo1 lung tissue showed poorly organized
peripheral lung tissue without well-formed air sacs (Figs. 3H, I).
To examine the efﬁciency and speciﬁcity of β-Catenin inactivation,
immunohistochemistry was used to localize β-Catenin protein.
Control lung tissue showed uniform staining for β-Catenin in both
epithelium and mesenchyme, while β-CateninDermo1 lungs showed
greatly reduced staining in lung mesenchyme as early as E12.5 (Figs.
3K, L) and complete absence of mesenchymal protein at E14.5 (Figs.
3M, N) and E18.5 (Supplemental Fig. 2). Epithelial β-Catenin
expression appeared unchanged throughout lung development. To
determine whether mesenchymal WNT signaling was reduced as a
consequence of inactivation of β-Catenin, expression of the WNT-β-
Catenin regulated genes, Lef1, N-Myc and CyclinD1 (see below), was
examined. Expression of Lef1 was decreased in β-CateninDermo1 lung
mesenchyme at E12.5 (Figs. 4A–D). Immunohistochemistry revealed
an absence of LEF1 protein in lung mesenchyme at E12.5 in β-Cate-
ninDermo1 lungs (Figs. 4E, F). These data demonstrate down-regulation
of mesenchymalWNT-β-Catenin signaling following inactivation of β-
Catenin in lung mesenchyme. Interestingly, Wnt2a expression was
also reduced in β-CateninDermo1 lungs (Figs. 4G, H), suggesting the
presence of a feedback loop downstream of β-Catenin that regulates
WNT-β-Catenin signaling (see below).
To determine whether lung epithelial WNT-β-Catenin signaling
was affected by inactivation of β-Catenin in lung mesenchyme, N-Myc
expression was examined. N-Myc is expressed in lung epithelium and
is a gene known to be regulated by epithelialWNT-β-Catenin signaling
(Shu et al., 2005). In situ hybridization analysis showed that, at E12.5,
N-Myc expressionwas not signiﬁcantly affected by inactivation of lung
mesenchymal β-Catenin (Figs. 4I, J). Additionally, Wnt7b, a WNT
ligand expressed in lung epithelium that signals through canonical
WNT-β-Catenin pathways, showed slightly increased expression
in β-CateninDermo1 lung epithelium compared to wild type controls
(Figs. 4K, L).
Mesenchymal β-Catenin is required for proliferation and survival of lung
mesenchymal and epithelial cells
The smaller size of β-CateninDermo1 lungs between E12.5 and E14.5,
and the failure to grow after E14.5, suggested that inactivation of
β-Cateninmay lead to decreased proliferation or increased cell death in
lung mesenchyme and may secondarily affect growth and survival of
lung epithelium. We assessed cell proliferation by examining ex-
pression of proliferating cell nuclear antigen (PCNA), as well as
incorporation of bromodeoxyuridine (BrdU). PCNA labels all cycling
cells, while BrdU speciﬁcally labels cells that are within S phase during
the labeling period. At E12.5 and E14.5, BrdU labeling was signiﬁcantly
decreased in β-CateninDermo1 lung tissue compared to control (Figs. 5A–
D). Quantitation revealed decreased proliferation within both the
epithelial and mesenchymal compartments (Table 1). To further
examine cell cycle progression, we examined the level of phospho-histone H3 (pHH3), a marker expressed during G2/M, by immunohis-
tochemistry. At E12.5, pHH3 labeling was signiﬁcantly decreased in β-
CateninDermo1 lungmesenchyme, but not in epithelium (Figs. 5E, F, Table
1). By contrast, at E14.5, pHH3 labelingwas signiﬁcantly decreased in β-
CateninDermo1 lung in both mesenchyme and epithelium (Figs. 5G, H,
Table 1). Surprisingly, despite severe hypoplasia of β-CateninDermo1 lung
tissue, there was an apparent increase in the PCNA labeling index
(number of PCNA-positive nuclei/total nuclei) in both themesenchymal
Fig. 5.Mesenchymal β-Catenin is required for proliferation and survival of lung mesenchymal and epithelial cells. (A–D) BrdU labeling was signiﬁcantly decreased in β-CateninDermo1
lung tissue at E12.5 (B) and E14.5 (D) compared to control lungs (A, C). (E–H) Immunostaining showing decreased phospho-histone H3 (pHH3) labeling in β-CateninDermo1 lung tissue
at E12.5 (F) and E14.5 (H) compared with the controls (E, G). (I–L) Immunostaining showing decreased Cyclin D1 expression in β-CateninDermo1 lung mesenchyme at E12.5 (J) and
E14.5 (L) compared with controls (I, K). Note that in epithelium, decreased Cyclin D1 expression was only observed at E14.5 (L). (M–R) Cell death assessed by TUNEL labeling in
β-CateninDermo1 embryonic lungs at E12.5 (M, N), E14.5 (O, P) and E18.5 (Q, R). No increased cell death was detected in β-CateninDermo1 lung tissue at E12.4 and E14.5 (M–P). At E18.5,
massive apoptosis was apparent throughout β-CateninDermo1 lung epithelium and mesenchyme (R) compared to control (Q). Scale bars: panels A and K, 50 μm; panels C, E, G, I,
100 μm; panels N, P, R, 200 μm.
431Y. Yin et al. / Developmental Biology 319 (2008) 426–436and epithelial compartments at E14.5 (Table 1, Supplemental Fig. 3),
suggesting an arrest in the cell cycle at the G1/S boundary and
accumulation of PCNA-positive, G1/S arrested cells. Together, the data
suggest that removal of mesenchymal β-Catenin results in an initialTable 1
Quantiﬁcation of proliferation markers in control and β-CateninDermo1 lungs
E12.5 (n=3)a
Epithelium Mesenchyme
Control CKO Control CKO
PCNA 474±10b 481±11 471±18 477±9
BrdU 394±26 286±25⁎ 356±35 219±3
p-HH3 12±3 9±1 25±3 14±2
CyclinD1 483±12 345±4# 87±8 21±7
p-ERK 7±4 4±4 5±1 1±1
CKO, β-CateninDermo1 conditional knockout.
⁎: pb0.01; #: pb0.05, Student's t test.
a Number of embryos analyzed. Two–three sections per embryo were counted.
b Cell index is deﬁned as the number of positive epithelial or mesenchymal nuclei/500 nsigniﬁcant reduction in the proliferation rate of mesenchymal cells and
an apparent secondary defect in epithelial proliferation.
D type Cyclins are required for progression through the cell cycle
(Baldin et al., 1993) and their expression is controlled by extracellularE14.5 (n=3)a
Epithelium Mesenchyme
Control CKO Control CKO
172±26 337±16⁎ 212±15 365±10⁎
4⁎ 215±5 141±9⁎ 187±19 140±15⁎
⁎ 16±2 1±1⁎ 23±2 1±1⁎
⁎ 417±10 224±18⁎ 80±9 26±6⁎
# 26±7 8±3# 17±4 7±3#
uclei counted.
432 Y. Yin et al. / Developmental Biology 319 (2008) 426–436growth factors, including members of the WNT and FGF family (Issack
and Ziff, 1998; Lobjois et al., 2004). At E12.5 and E14.5, Cyclin D1
expression was reduced in β-CateninDermo1 lung mesenchyme and
epithelium (Figs. 5I–L, Table 1). The decrease in epithelium appeared
greater at E14.5 (Figs. 5K, L).
Cell death was examined by TUNEL labeling. At E12.5 and E14.5, no
signiﬁcant increase in cell death was detected in β-CateninDermo1 lung
tissue (Figs. 5M–P). However, at E18.5,massive apoptosiswas apparent
throughout lung epithelium andmesenchyme (Figs. 5Q, R). These data
indicate that mesenchymalWNT-β-Catenin signaling is either directly
required for cell survival after E14.5, that proper WNT-β-Catenin
signaling at earlier stages is necessary for lung viability at later times in
development, or that other phenotypes affect lung survival at later
stages of development. Further studies were therefore focused on
earlier developmental stages (E12.5–E14.5) to identify more direct
functions of WNT-β-Catenin signaling in lung mesenchyme.
Taken together, these data demonstrate that mesenchymal WNT-
β-Catenin signaling is essential for maintaining lung mesenchymal
proliferation. This could be a direct consequence of WNT regulation of
cell cycle genes or an indirect effect mediated through regulation of
other signaling pathways. Additionally, non-autonomous effects on
lung epithelial proliferation suggest loss of a mesenchymal-derived
signal to epithelial cells.
Epithelial identity and signaling in β-CateninDermo1 lung
To further examine lung epithelial function in β-CateninDermo1 lung,
Thyroid Transcription Factor 1 (TTF1) and Surfactant Protein-C (SP-C)
expression was examined. TTF1 is essential for epithelial cellFig. 6. Deﬁciency of lung mesenchymal WNT-β-Catenin signaling does not affect epithe
epithelium of control (A, C) and β-CateninDermo1 lung (B, D) at E12.5 and E14.5. (E–H)Whole-
Fgf10 in control (E, G) and β-CateninDermo1 lungs (F, H). (I–L) Whole-mount in situ hybridizatio
K) and β-CateninDermo1 lung (J, L). Scale bars: in panels A and C, 50 μm; in panels E and I, 20development (Cardoso and Lu, 2006) and SP-C is expressed in distal
lung epithelium (Weaver et al., 1999). Immunostaining for TTF1
demonstrated expression in epithelial cell nuclei at near normal levels
at E12.5 and E14.5 in β-CateninDermo1 lung (Figs. 6A–D), similar towhat
was observed in Fgfr1/2Dermo1 lung (data not shown). Expression of
SP-C was reduced in β-CateninDermo1 lung at E12.5 (data not shown).
FGF10 is an essential factor for lung epithelial branching. Focal
Fgf10 expression is observed in mesenchyme at the distal tip of the
prospective lung lobes starting at ~E10.0 and in distal mesenchyme
adjacent to budding airway epithelium at later stages (Bellusci et al.,
1997). Expression patterns of Fgf10 were examined to determine
whether altered FGF10 expression could account for some of the
epithelial phenotypes observed in β-CateninDermo1 lung. At E12.0 and
E14.5, control and β-CateninDermo1 lungs exhibited comparable
expression patterns and levels of Fgf10 in mesenchyme distal to
budding airways (Figs. 6E–H). To examine FGF signaling in lung
epithelium, Sprouty 2 (Spry2) expression was examined. Spry2 is one
of the earliest targets to be induced in the lung epithelium in response
to FGF10 (Mailleux et al., 2001) and is a negative regulator of the FGF
signaling pathway. Comparison of Spry2 expression showed no
signiﬁcant difference in control and β-CateninDermo1 lungs at E12.5
and E14.5 (Figs. 6I–L), further suggesting that FGF10-FGFR2b signaling
is not a primary target of mesenchymal WNT-β-Catenin signaling.
WNT-β-Catenin signaling regulates FGF receptor expression and function
in lung mesenchyme
Mesenchymal proliferation is decreased in Fgf9−/−, Fgfr1/2Dermo1
and in β-CateninDermo1 lung tissue. We hypothesized that thelial FGF signaling. (A–D) Immunostaining shows comparable TTF1 expression in the
mount in situ hybridization at E12.5 (E, F) and E14.5 (G, H) showing comparable levels of
n shows comparable levels of Spry2 expression at E12.5 (I, J) and E14.5 (K, L) in control (I,
0 μm; in panels G and K, 500 μm.
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mediated in part through regulation of FGF signaling. Fgfr1 and FGFR2
expression was therefore examined. Immunostaining of E12.5 lung
showed decreased expression of FGFR2 in β-CateninDermo1 lung
mesenchyme but not in epithelium (Figs. 7A, B). At E14.5, FGFR2
expression was not detectable in lung mesenchyme but still was
expressed at normal levels in distal epithelium (Figs. 7C, D).
To further examine the regulation of lung mesenchymal Fgfr2
expression by mesenchymal WNT-β-Catenin signaling, we exam-
ined expression of Fgfr2 in E14.5 lung tissue from control and
β-CateninDermo1 mice by quantitative RT-PCR. In the absence of
mesenchymal WNT-β-Catenin signaling, Fgfr2 showed 4.6 fold lower
expression (Fig. 7E). To further test the ability of WNT-β-Catenin
signaling to regulate Fgfr2 gene expression, wild type lung explants
were treated with 20 mM LiCl for 48 h. LiCl inhibits GSK3β and
stabilizes and activates cytosolic β-Catenin (Klein and Melton, 1996).
Quantitative RT-PCR showed that in the presence of LiCl, Fgfr2
expression was increased 6.8 fold (Fig. 7F). Finally, 6.8 kb of Fgfr2
genomic sequence, located 5′ to the transcription initiation site,
was cloned into a luciferase expression plasmid, pGL3 basic.
Co-transfection with pCIG-dominant active β-catenin, containing a
constitutively active form of β-Catenin, resulted in a 4.6 fold inc-
rease in luciferase activity relative to controls (co-transfection with
pCIG) (Fig. 7G).
Fgfr1 mRNA expression was examined by whole-mount in situ
hybridization. Fgfr1 showed reduced expression in lung mesenchyme
at E12.5 (Figs. 7H, I) and E14.5 (Figs. 7J, K). Epithelial expression wasFig. 7.WNT-β-Catenin signaling regulates FGF receptor expression in lung mesenchyme. (A–
mesenchyme and epithelium (A, C) and the absence of FGFR2 expression in lung mesenchym
Fgfr2 expression showing decreased expression in E14.5 β-CateninDermo1 lung (βCatDermo1)
showing increased expression of E11.5 lung explants treated with 20 mM LiCl for 48 h compa
increased activity in response to co-transfection of HEK293 cells with a dominant active β-C
plasmid. ⁎, pb0.05; ⁎⁎, pb0.001 (Student's t test). Error bars show SEM. (H–K) In situ hybridiz
expression in control mesenchyme and epithelium (H, J) and reduced Fgfr1 expression in β-
decreased expression of p-ERK at E14.5 in β-CateninDermo1 lung (M) compared with the conalso decreased at E14.5 in β-CateninDermo1 lungs (Fig. 7K). Consis-
tent with decreased FGFR expression and decreased mesenchy-
mal proliferation, p-ERK expression was decreased throughout
β-CateninDermo1 lungs at E14.5 (Figs. 7L, M, Table 1).
If decreasedmesenchymal FGFR expression in β-CateninDermo1 lung
was functionally important, one would predict that β-CateninDermo1
lungs would have impaired responsiveness to FGF ligands that
primarily signal to mesenchymal FGFRs. To test this, lung explant
cultures from control and β-CateninDermo1 lungs were treatedwith BSA
or FGF9 (Figs. 8A–E). Control lung explants responded to FGF9 with
mesenchymal hyperplasia, as we have previously reported (White et
al., 2006) (Figs. 8A, B). Measurement of mesenchymal thickness in
control lung explants showed a 2.8 fold (pb0.01) increase in response
to FGF9 (Fig. 8E). In contrast, β-CateninDermo1 lung explants showed no
signiﬁcant mesenchymal response to FGF9, and the sub-mesothelial
mesenchymal layer remained thin, similar to BSA treated explants
(Figs. 8C–E). Of note, epithelium in both control and β-CateninDermo1
lungs showed a dilation in response to FGF9 (Fig. 8B, D), consistent
with the possibility that FGF9 may also signal directly to lung epi-
thelium (del Moral et al., 2006).
Another prediction that arises from this regulatory network model
is that, in the absence of FGF9, the feedback loop that maintains
WNT-β-Catenin signaling and Fgfr expression should degrade and lung
explants from Fgf9−/− embryos should not be able to be rescued by
treatment with FGF9. Consistent with this prediction, Fgf9−/− lung
explants showed nomesenchymal response to FGF9 (Figs. 8H–J), while
control mesenchyme showed a 2.7 fold increase in mesenchymalD) Immunostaining of E12.5 and E14.5 lung showing FGFR2 expression in control lung
e but not epithelium in β-CateninDermo1 lung (B, D). (E) Quantitative-RT-PCR detection of
compared to control lung (Con). (F) Quantitative-RT-PCR detection of Fgfr2 expression
red to untreated control explants. (G) Fgfr2 promoter-luciferase reporter gene showing
atenin expression plasmid (βCat⁎), compared to control cells transfected with the pCIG
ation (cryo-section of whole-mount) of E12.5 (H, I) and E14.5 (J, K) lungs showing Fgfr1
CateninDermo1 lung mesenchyme and epithelium (I, K). (L, M) Immunostaining showing
trol lung (L). Scale bars: panels A, C, H, J, L, 50 μm.
Fig. 8. β-CateninDermo1 and Fgf9−/− lung mesenchyme have a decreased response to FGF9. (A–D) Lung explant cultures from control (A, B) and β-CateninDermo1 lungs (C, D) were
treated with BSA (A, C) or FGF9 (B, D). Control lung explants responded to FGF9 (B), but not to BSA (A), with mesenchymal hyperplasia. In contrast, β-CateninDermo1 lungs showed a
similar lack of response to both BSA (C) and FGF9 (D). (E) Quantitation of mesenchymal growth in response to BSA and FGF9 (n=3, ⁎pb0.01). (F–I) Lung explant cultures from
control (F, G) and Fgf9−/− lungs (H, I) were treated with BSA (F, H) or FGF9 (G, I). Control lung explants responded to FGF9 (G), but not to BSA (F), with mesenchymal hyperplasia. In
contrast, Fgf9−/− lungs showed a similar lack of response to both BSA (H) and FGF9 (I). (J) Quantitation of mesenchymal growth in response to BSA and FGF9 (n=3, ⁎pb0.01). Scale
bars: D, I, 200 μm.
434 Y. Yin et al. / Developmental Biology 319 (2008) 426–436thickness in response to FGF9 (Figs. 8F, G, J). Epithelium from both
control and Fgf9−/− explants showed epithelial dilation in response to
FGF9 (Figs. 8F–I).
Discussion
We have identiﬁed a robust regulatory circuit inwhich epithelial to
mesenchymal FGF signaling regulates the expression of a Wnt ligand
and the level of WNT-β-Catenin signaling, and in which mesenchymal
WNT-β-Catenin signaling regulates the expression of FGF receptors
and the level of mesenchymal FGF signaling (Fig. 9). The only external
(non-mesenchymal) factor that has thus far been identiﬁed that can
modulate this signaling system is FGF9, which is produced by the
mesothelial lining of the lung and by airway epithelium, and poten-
tially WNT7b, which is produced in airway epithelium. The primary
output of this system appears to be regulation of mesenchymal pro-
liferation, but clearly other mesenchymal factors that regulate lung
epithelial proliferation, survival and differentiation must also act
downstream of FGF and/or β-Catenin.
Two predictions can be derived from the FGF–WNT interaction
model (Fig. 9). First: down-regulation or inhibition of any component
of this system should diminish the output of the entire system.
Second: up-regulation of any component of the system should rein-
force the entire system. In vitro organ culture experiments and in vivogenetic experiments support the circular and self-sustaining nature of
this signaling network. For example, lung tissue lacking mesenchymal
β-Catenin was predicted and shown to down-regulate mesenchymal
responsiveness to FGF9. Similarly, loss of mesenchymal FGF signaling
resulted in diminished WNT-β-Catenin signaling, loss of Fgfr expres-
sion and inability of the tissue to be rescued by treatment with FGF9.
However, phenotypic differences resulting from loss of either
mesenchymal β-Catenin or mesenchymal FGFR1 and FGFR2 indicate
that other factors must also feed into this signaling circuit to sustain
mesenchymal viability. Apparent differences could also be due to
variation in the timing or efﬁciency of Cre-mediated inactivation of
β-Catenin and Fgfrs 1 and 2, versus complete loss of mesenchymal
FGF signaling in Fgf9−/− lungs. In FGF loss of function models (Fgf9−/−
and Fgfr1/2Dermo1), the lung becomes atrophic by birth but does not
exhibit widespread cell death (Colvin et al., 2001; White et al., 2006).
By contrast, β-CateninDermo1 lungs exhibit widespread apoptosis by
E18.5. These observations provide further evidence that these two
pathways are not equivalent and that β-Catenin signaling may have a
more important role in mesenchymal cell survival. Furthermore,
some intrinsic or extrinsic signal(s) likely maintains low-level
mesenchymal β-Catenin signaling and cell viability in the absence
of FGF signaling. This is supported by the observed reduction, but not
elimination, of WNT-β-Catenin activity (Lef1 expression) in Fgf9−/−
lung mesenchyme. However, besides FGF9 and WNT7b, factors that
Fig. 9.Molecular pathways by whichWNT-β-Catenin and FGF regulate lung mesenchymal development. (1) At early stages of lung development (E10–E12), FGF9 is produced by lung
mesothelium and epithelium and signals to mesenchymal FGFR1c and FGFR2c to maintain mesenchymal proliferation (Colvin et al., 2001; White et al., 2006). In the absence of Fgf9,
expression of the mesenchymalWNT-β-Catenin pathway ligand,Wnt2a, and target gene, Lef1, was down-regulated. When FGF9 was overexpressed in airway epithelium,Wnt2a, and
the β-Catenin target gene, Lef1, were both up-regulated. This suggests a signaling pathway in which mesenchymal FGFR activation regulatesWnt2a expression (2) and mesenchymal
WNT-β-Catenin signaling. (3) Inactivation of mesenchymal β-Catenin resulted in decreased expression of Lef1 mRNA and protein, decreased expression of CyclinD1 and decreased
mesenchymal proliferation, suggesting that mesenchymal WNT signaling could mediate, in part, FGF regulated mesenchymal proliferation. (4) Inactivation of mesenchymal
β-Catenin also resulted in decreased expression of FGFR1 and FGFR2 in lung mesenchyme, suggesting that feedback through FGFR signaling may contribute to the ability of
mesenchymal WNT signaling to regulate proliferation (5) and Wnt2a expression (2). (6) Wnt7b is expressed in airway epithelium and likely signals to mesenchyme to regulate
WNT-β-Catenin signaling. Red stippled area represents the Wnt2a expression domain in the sub-mesothelial mesenchymal compartment.
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identiﬁed.
Wnt7b is expressed in lung epithelium (Pepicelli et al., 1998;
Weidenfeld et al., 2002). Wnt7b−/− embryos have reduced lung
mesenchymal proliferation and defects in lung vascular smooth
muscle (Shu et al., 2002). It is, therefore, likely that WNT7b signals
directly to adjacent sub-epithelial mesenchyme and acts synergisti-
cally or redundantly with WNT2a (Fig. 9). Wang et al. (2005) have
shown that WNT7b can activate FZD1, 4 and 7 and that these WNT
receptors are expressed in lung mesenchyme and in vascular smooth
muscle precursors; however, direct targets of WNT-β-Catenin signal-
ing were not examined in lung mesenchyme of Wnt7b−/− mice.
Supporting the idea that WNT7b could regulate mesenchymal WNT-
β-Catenin activity independent of FGF9, we showed that the
expression of Wnt7b was increased in Fgf9−/− lungs. Thus, WNT7b is
likely to be a second independent external factor that can modulate
the mesenchymal WNT-β-Catenin–FGFR regulatory circuit.
Lef1, a target of WNT-β-Catenin signaling, appears to be uniformly
expressed throughout distal mesenchyme. This suggests that Wnt2a,
which is expressed in sub-mesothelial mesenchyme, might support
both autocrine signaling to sub-mesothelial mesenchyme and para-
crine signaling to sub-epithelial mesenchyme. Although a lung
mesenchymal phenotype was not reported for Wnt2a−/− mice
(Monkley et al., 1996) and the original knockout line was not saved,
a second, recently constructed line ofWnt2a−/− mice shows decreased
lung mesenchymal proliferation (E. Morrisey, personal communica-
tion). Additionally,Wnt7b−/− mice show decreased lung mesenchymal
proliferation (Shu et al., 2002). These data support a potential role for
these ligands acting together in the regulation of mesenchymal WNT-
β-Catenin signaling. To demonstrate this in vivo, future epistasis
studies will be required in which Wnt2a and Wnt7b double hetero-
zygous mice are examined.To address the contribution of WNT-β-Catenin signaling in lung
epithelium, several labs have conditionally inactivated β-Catenin in
epithelium or overexpressed the WNT antagonist, DKK, in epithelium
(De Langhe et al., 2005; Mucenski et al., 2003; Shu et al., 2005). These
studies showed that WNT-β-Catenin signaling regulates the expres-
sion of N-Myc, Bmp4 and Fgfr2b in lung epithelium and regulates the
extent of branching morphogenesis. Down-regulation of epithelial
Fgfr2b could account for the observed defects in branching morpho-
genesis in these mice. Importantly, the identity of the WNT ligand(s)
that regulates epithelial WNT-β-Catenin signaling is not known;
however, in addition to activating FZD1, 4 and 7 in lung mesenchyme,
WNT7b can activate FZD10, which is expressed in lung epithelium
(Wang et al., 2005). A possible autocrine role for WNT7b in epithe-
lium is supported by observed defective epithelial differentiation in
Wnt7b−/− lung tissue (Shu et al., 2002).
In summary, FGF9, and most likely WNT7b, are two ligands that
can independently signal from mesothelial (FGF9) and epithelial
(FGF9 and WNT7b) cells to lung mesenchyme to regulate growth. The
positive feedback loop within the mesenchymal compartment
(Wnt2a, FGFR1, FGFR2 and β-Catenin) allows input from both FGF
and WNT signaling systems to modulate the output of the entire
system, thus providing a mechanism to tightly regulate mesenchymal
lung development and, indirectly, epithelial morphogenesis.
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